Immune therapies against chronic hepatitis B

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Chronic hepatitis B (CHB) poses significant health risks, including liver cirrhosis and cancer.
• Current antiviral treatments for hepatitis B virus (HBV) cannot fully eradicate the virus or prevent disease progression in many patients.
• Immune dysregulations are implicated in HBV persistence and liver damage, suggesting immunotherapy as a potential treatment strategy.

Purpose of the Study:

• To review the pros and cons of various immune therapies used for CHB over the past 30 years.
• To provide insights for developing effective, evidence-based, and patient-friendly immune treatment regimens for CHB.
• To address the unmet need for novel therapeutics in CHB management.

Main Methods:

• Review of clinical trials and scientific literature on immune therapies for CHB from the early 1990s to the present.
• Analysis of the safety and efficacy of different immunotherapeutic agents and protocols.
• Discussion of molecular and cellular mechanisms underlying CHB pathogenesis and immune responses.

Main Results:

• Despite extensive research and hundreds of clinical trials, an optimal immune therapy regimen for CHB has not yet been established.
• Most immune therapeutic agents demonstrate good safety profiles in patients.
• Several immune therapy protocols have shown encouraging results, fostering optimism for future treatments.

Conclusions:

• Immune therapy remains a critical area of research for CHB, offering a potential alternative or adjunct to antiviral therapy.
• Further research is needed to overcome existing challenges and develop a universally acceptable immune therapy regimen.
• The insights gained from 30 years of immune therapy research are crucial for advancing CHB treatment strategies.